Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Budesonid (FAM Kinpeygo und austauschbare Arzneimittel), ATC A07EA06 für die Zeit 01.08.2026 - 31.07.2028

DAK-GesundheitHamburg, GermanyEUR 1 / ~EUR 1717 days leftopen

Registrieren zum Speichern Documents (1)

Opportunity Score

Confidence: 50%

Complexity: low

717 days

Deadline

supplies

Contract

Deep Portfolio Analysis

Company fit score
Missing certificates
Eligibility blockers
Bid / No-Bid recommendation

Create account for AI analysis

AI Analysis Summary

Moderate opportunity

Non-exclusive discount agreement (open-house model) for Budesonide (FAM Kinpeygo and interchangeable drugs), ATC A07EA06, for the period 01.08.2026-31.07.2028. The procedure is not a formal procurement under GWB but a voluntary transparency publication. Any pharmaceutical company can join at any time by submitting required documents via email. Initial contracts start 01.08.2026; later additions possible on the 1st or 15th of each month if documents are received by the 5th of the previous month.

Strengths

Documents available

Open procedure

Low complexity

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Submit completed application letter (Angebotsschreiben)
Acknowledge and sign the contract including specified discounts
Fill and submit Annex 1 and Annex 2 (Annex 2 must be an Excel file)

Buyer

Name

DAK-Gesundheit

Location

Hamburg, DEU

[email protected]

Website

www.dak.de

Identifier

DE48698890

Lots (1)

#LOT-0001Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Budesonid (FAM Kinpeygo und austauschbare Arzneimittel), ATC A07EA06 für die Zeit 01.08.2026 - 31.07.2028

Single lot covering all pharmaceutical products containing Budesonide (FAM Kinpeygo and interchangeable drugs) under ATC code A07EA06. The agreement is a non-exclusive discount contract open to all interested pharmaceutical companies.

EUR 133600000DEU